General Information of Drug (ID: DM7WXJ9)

Drug Name
PMID29130358-Compound-Figure18(14) Drug Info
Cross-matching ID
TTD Drug ID
DM7WXJ9

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Discontinued Drug(s)
Investigative Drug(s)
Approved Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Curcumin DMQPH29 Solid tumour/cancer 2A00-2F9Z Phase 3 [2]
Apratastat DM8W4N9 Rheumatoid arthritis FA20 Phase 2 [3]
PMID17935984C1 DMO1IHL Pain MG30-MG3Z Clinical trial [4]
PMID29130358-Compound-Figure18(14a) DMHIBTZ N. A. N. A. Patented [1]
PMID29130358-Compound-Figure16(9b) DMPAQLZ N. A. N. A. Patented [1]
PMID29130358-Compound-Figure16(9a) DMKX5R8 N. A. N. A. Patented [1]
PMID29130358-Compound-Figure16(9c) DM0ZRI9 N. A. N. A. Patented [1]
GM6001 DM7V9CT Corneal ulcer 9A76 Discontinued in Phase 2 [5]
RS-130830 DMOTANY Hepatitis C virus infection 1E51.1 Discontinued in Phase 2 [6]
MMI270 DM38N2K Discovery agent N.A. Investigative [7]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Prinomastat DM9HOKG Lung cancer 2C25.0 Approved [8]
Epigallocatechin gallate DMCGWBJ Hepatic fibrosis DB93.0 Phase 3 [9]
Marimastat DM6V34C Pancreatic cancer 2C10 Phase 3 [10]
Neovastat DMXTYWJ Non-small-cell lung cancer 2C25.Y Phase 1 [11]
Metastat DMTQ4PN Acne vulgaris ED80 Phase 1 [12]
PMID29130358-Compound-Figure18(14a) DMHIBTZ N. A. N. A. Patented [1]
PMID29130358-Compound-Figure10(2a) DMFWXPS N. A. N. A. Patented [1]
PMID29130358-Compound-Figure16(9b) DMPAQLZ N. A. N. A. Patented [1]
PMID29130358-Compound-SB-3CT DMC64XQ N. A. N. A. Patented [1]
PMID29130358-Compound-Figure16(9a) DMKX5R8 N. A. N. A. Patented [1]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Matrix metalloproteinase-13 (MMP-13) TTHY57M MMP13_HUMAN Inhibitor [1]
Matrix metalloproteinase-2 (MMP-2) TTLM12X MMP2_HUMAN Inhibitor [1]

References

1 Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46.
2 High throughput screening of potentially selective MMP-13 exosite inhibitors utilizing a triple-helical FRET substrate. Bioorg Med Chem. 2009 Feb 1;17(3):990-1005.
3 Acetylenic TACE inhibitors. Part 3: Thiomorpholine sulfonamide hydroxamates. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1605-9.
4 Potent, selective spiropyrrolidine pyrimidinetrione inhibitors of MMP-13. Bioorg Med Chem Lett. 2007 Dec 1;17(23):6529-34.
5 Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia si... J Biol Chem. 2007 Sep 21;282(38):27781-91.
6 Structure-based design of potent and selective inhibitors of collagenase-3 (MMP-13). Bioorg Med Chem Lett. 2005 Feb 15;15(4):1101-6.
7 Heterocycle-based MMP inhibitors with P2' substituents. Bioorg Med Chem Lett. 2001 Apr 23;11(8):1009-13.
8 AG-3340 (Agouron Pharmaceuticals Inc). IDrugs. 2000 Mar;3(3):336-45.
9 Regioselective synthesis of methylated epigallocatechin gallate via nitrobenzenesulfonyl (Ns) protecting group. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4171-4.
10 Metalloelastase (MMP-12) induced inflammatory response in mice airways: effects of dexamethasone, rolipram and marimastat. Eur J Pharmacol. 2007 Mar 15;559(1):75-81.
11 Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials. Semin Oncol. 2001 Dec;28(6):620-5.
12 Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer. 2002 Sep;2(9):657-72.